On February 26, 2026, Boston Scientific Corp entered into a $3 billion revolving credit agreement and a $6 billion term loan agreement, both to finance its acquisition plans, while terminating a prior agreement from 2021. These agreements set specific leverage ratios and interest rates based on the company's credit rating, ensuring financial flexibility for future investments.